Search | Clinical Trials Finder

Conditions: Hypersensitivity, Immediate
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 19 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Seasonal Allergic Rhinitis (SAR)
Interventions: GSP 301 NS, GSP 301 Placebo NS; Drug
Lead sponsor: Glenmark Specialty S.A.; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 32
States / cities: Mission Viejo, California • Ontario, California • Paramount, California + 26 more

Conditions: Rhinitis, Allergic, Seasonal
Interventions: Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals), Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray, Placebo; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 12 Years and older
Enrollment: 727 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 7
States / cities: Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more

Conditions: Perennial Allergic Rhinitis
Interventions: ciclesonide hydrofluoroalkane (HFA) nasal aerosol, mometasone nasal inhalation; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 6
States / cities: Mission Viejo, California • San Diego, California • North Dartmouth, Massachusetts + 3 more

Conditions: Allergic Rhinitis, Allergic Conjunctivitis, Atopic Dermatitis
Interventions: XmAb7195, Placebo; Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Nasal Polyps, Asthma, Aspirin-Induced, Aspirin-Exacerbated Respiratory Disease, Aspirin-Sensitive Asthma With Nasal Polyps
Interventions: Dupilumab; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rhinitis, Allergic, Seasonal
Interventions: Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate, Histamine base; Biological
Lead sponsor: Dynavax Technologies Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 738 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 28
States / cities: Oxford, Alabama • Stockbridge, Georgia • Normal, Illinois + 22 more

Conditions: Rhinosinusitis, Chronic Eosinophilic Rhinosinusitis, Allergic Rhinosinusitis
Interventions: Budesonide, Saline alone; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Allergic Rhinitis, Asthma, Back Pain, Benign Prostatic Hypertrophy, Bursitis, Depression, Anxiety, Diabetes Mellitus, Esophageal Reflux, HIV Infections, Hyperlipidemia, Hypertension, Insomnia, Irritable Bowel Syndrome, Obesity, Osteoporosis (Senile), Shoulder Pain, Sinusitis, Symptomatic Menopause, Urinary Incontinence, Urinary Tract Infection, Vaginitis
Interventions: Health Information Prescription; Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Perennial Allergic Rhinitis
Interventions: ciclesonide, mometasone; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 15
States / cities: Huntington Beach, California • Mission Veijo, California • San Diego, California + 11 more

Conditions: Meniere Disease, Allergic Rhinitis, Vertigo
Interventions: Montelukast, Placebo; Drug
Lead sponsor: House Ear Institute; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Rhinitis, Allergic, Perennial
Interventions: Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol, Placebo Nasal Aerosol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 35
States / cities: Los Angeles, California • Mission Viejo, California • San Diego, California + 30 more

Conditions: Allergic Asthma, Allergy to Cats, Allergy to Dust Mites, Allergic Rhinitis, Allergic Conjunctivitis
Interventions: Segmental allergen challenge; Biological
Lead sponsor: JOSALYN CHO; Other
Eligibility: 18 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Iowa City, Iowa • Boston, Massachusetts

Conditions: Seasonal Allergic Rhinitis
Interventions: MP29-02, azelastine Hcl, fluticasone propionate, placebo; Drug
Lead sponsor: Meda Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 607 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 7
States / cities: Austin, Texas • New Braunfels, Texas • San Antonio, Texas + 1 more

Conditions: Asthma, Lung Function Decreased, Food Allergy, Allergic Sensitisation, Allergic Rhinitis, COPD, Atopy
Interventions: Dietary intake of various nutrients, foods and biocompounds; Other
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 15 Years to 75 Years
Enrollment: 3,500 participants
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Asthma
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years to 21 Years
Enrollment: 40 participants
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Asthma
Interventions: HA115, Placebo; Drug
Lead sponsor: Conjupro Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Rhinitis, Allergic, Seasonal
Interventions: GW685698X Aqueous Nasal Spray; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 18
States / cities: Chicago, Illinois • Indianapolis, Indiana • Lafayette, Indiana + 14 more

Conditions: Perennial Allergic Rhinitis With Seasonal Variation
Interventions: allergen immunotherapy; Other
Lead sponsor: United Allergy Services; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Rhinitis, Allergic, Perennial
Interventions: GW685698X; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 43
States / cities: Little Rock, Arkansas • Los Angeles, California • Mission Viejo, California + 37 more

Conditions: Allergic Rhinitis
Interventions: live attenuated influenza virus (LAIV) with clean air, LAIV and diesel exhaust particles; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 35 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Seasonal Allergic Rhinitis
Interventions: azelastine hydrochloride and fluticasone propionate, Dymista vehicle; Drug
Lead sponsor: Meda Pharmaceuticals; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 31
States / cities: Birmingham, Alabama • Little Rock, Alaska • Atlanta, Georgia + 24 more

Conditions: Perennial Allergic Rhinitis
Interventions: levocetirizine (Xyzal), placebo; Drug
Lead sponsor: AAADRS Clinical Research Center; Other
Eligibility: 12 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: Seasonal Allergic Rhinitis (SAR)
Interventions: GSP 301 NS, GOM-NS, GMM-2 NS, GSP 301 placebo NS; Drug
Lead sponsor: Glenmark Specialty S.A.; Industry
Eligibility: 12 Years and older
Enrollment: 1,176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 43
States / cities: Mission Viejo, California • Orange, California • San Diego, California + 33 more

Search by objective public record fields.

Clinical and Immunological Evaluation of Children With Allergies

Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)

A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis

Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis

Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease

Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults

The Impact Of The Addition Of Budesonide To Low-Pressure, High-Volume Saline Sinus Irrigation For Chronic Rhinosinusitis

Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow

Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray

Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease

Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)

Airway Immune Response to Allergens (Use Lay Language Here)

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Dietary Intake in Adults From the GA2LEN Folow-up Survey

Examining Changes in Nasal IL-1 During Acute Asthma Exacerbation in Adolescents

Single and Multiple Doses of HA115 and Food Effect in Healthy Adult Volunteers

Once-Daily Investigational Nasal Spray In Adults And Adolescents With Seasonal Allergic Rhinitis (SAR)

The Efficacy & Safety of the UAS Immunotherapy Protocol

A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR).

Effects of Diesel Exhaust Followed by Administration of Nasal Spray Flu Vaccine on Individuals With & Without Allergies

Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)

Levocetirizine Effect on Nasal Nitric Oxide and Nasal Eosinophils in Subjects With Perennial Allergic Rhinitis

Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)